Phyllocladene

Phyllocladene

SCHEMBL29388334

C=C1C[C@]23CC[C@@H]4C(C)(C)CCC[C@@]4(C)[C@@H]2CC[C@H]1C3

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 4/20 0.72
HSD11B2 P80365 1/20 0.72
PTPN1 P18031 5/20 0.69
BCHE P06276 2/20 0.45
ACHE P22303 1/20 0.45
ALDH1A1 P00352 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
TSHR P16473 1/20 0.40
CYP2C19 P33261 1/20 0.40
PTPN2 P17706 2/20 0.38
RPS6KA5 O75582 2/20 0.36
MAPKAPK2 P49137 2/20 0.36
F10 P00742 1/20 0.34
CDC25B P30305 1/20 0.34
IDO1 P14902 1/20 0.34
ATM Q13315 1/20 0.34
PNLIP P16233 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phyllocladene SCHEMBL29437839 1.00 HSD11B1 (0.72) HSD11B1HSD11B2PTPN1BCHEACHE
Phyllocladene SCHEMBL1006869 1.00 HSD11B1 (0.72) HSD11B1HSD11B2PTPN1BCHEACHE
Phyllocladene SCHEMBL156928 1.00 HSD11B1 (0.72) HSD11B1HSD11B2PTPN1BCHEACHE
Phyllocladene SCHEMBL1006868 1.00 HSD11B1 (0.72) HSD11B1HSD11B2PTPN1BCHEACHE
Phyllocladene SCHEMBL16414456 0.88 PTPN1 (0.65) HSD11B1HSD11B2PTPN1BCHEACHE
Phyllocladene SCHEMBL20538769 0.88 PTPN1 (0.65) HSD11B1HSD11B2PTPN1BCHEACHE
SCHEMBL267551 0.84 HSD11B1 (1.00) HSD11B1HSD11B2PTPN1BCHEACHE
SCHEMBL20738425 0.84 HSD11B1 (1.00) HSD11B1HSD11B2PTPN1BCHEACHE
SCHEMBL3491660 0.84 HSD11B1 (1.00) HSD11B1HSD11B2PTPN1BCHEACHE
SCHEMBL21331728 0.84 HSD11B1 (1.00) HSD11B1HSD11B2PTPN1BCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11380884-B2 Liquid composition for producing electrode composite material, method for producing electrode, and method for producing electrochemical element RICOH COMPANY, LTD. (JP) 2022-07-05 US claimed
US-20260034186-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2026-02-05 US disclosed
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC (US) 2026-01-29 US disclosed
EP-4673510-A1 SOLVENT-BASED INKJET INKS Kao Corporation (JP) 2026-01-07 EP disclosed
US-12458653-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2025-11-04 US disclosed
EP-4640783-A1 TWO-PART CURABLE ADHESIVE, MULTILAYER BODY AND PACKAGE DIC Corporation (JP) 2025-10-29 EP disclosed
US-12427176-B2 Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products RIZUN NODARI (US) 2025-09-30 US disclosed
EP-3593390-B1 FILM ELECTRODE, RESIN LAYER FORMING INK AND ELECTRODE PRINTING METHOD RICOH CO LTD (JP) 2025-09-17 EP disclosed
EP-4567936-A2 FILM ELECTRODE, RESIN LAYER FORMING INK AND ELECTRODE PRINTING METHOD Ricoh Company, Ltd. (JP) 2025-06-11 EP disclosed
US-12303488-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2025-05-20 US disclosed
US-11684604-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2023-06-27 US disclosed
US-20230181665-A1 TREATING OR PREVENTING INFLAMMATORY DISEASES INCLUDING DIABETES MELLITUS 10 TYPE I AND TYPE II AND THYROID DISEASES Novel Concepts Medical Ltd (IL) 2023-06-15 US disclosed
US-20230134432-A1 COMPOSITIONS AND METHODS FOR TREATING SOLID AND SOFT TUMORS AND PROLIFERATIVE DISEASES Novel Concepts Medical Ltd (IL) 2023-05-04 US disclosed
US-20230091130-A1 FILM ELECTRODE, RESIN LAYER FORMING INK, INORGANIC LAYER FORMING INK, AND ELECTRODE PRINTING APPARATUS RICOH COMPANY, LTD. (JP) 2023-03-23 US disclosed
US-11588147-B2 Film electrode, resin layer forming ink, inorganic layer forming ink, and electrode printing apparatus RICOH COMPANY, LTD. (JP) 2023-02-21 US disclosed
WO-2022260020-A1 METHOD FOR ADJUSTING QUANTITY OF LIQUID RETURNED TO STORAGE CONTAINER FOR LIQUID PREPARATION IN INVERTED VOLATILIZATION DEVICE, AND INVERTED VOLATILIZATION DEVICE アース製薬株式会社 2022-12-15 WO disclosed
US-20220387537-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2022-12-08 US disclosed
US-11380884-B2 Liquid composition for producing electrode composite material, method for producing electrode, and method for producing electrochemical element RICOH COMPANY, LTD. (JP) 2022-07-05 US disclosed
US-20220085458-A1 POROUS INSULATOR, ELECTRODE, AND NONAQUEOUS POWER STORAGE ELEMENT RICOH COMPANY, LTD. (JP) 2022-03-17 US disclosed
US-11258136-B2 Porous insulator, electrode, and nonaqueous power storage element RICOH COMPANY, LTD. (JP) 2022-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11684604-B2 Cannabis based therapeutic and method of use CNR2, CNR1, OPRK1 HSD11B1 3153/4885HSD11B2 3207/4885PTPN1 2536/4885
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE CNR1, CNR2, OPRM1 HSD11B1 406/4885HSD11B2 840/4885PTPN1 1893/4885
US-20260034186-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS TRPV1, SOST, RUNX1 HSD11B1 674/4885HSD11B2 640/4885PTPN1 4282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.